Compare MRAM & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MRAM | AVIR |
|---|---|---|
| Founded | 2008 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 372.1M | 334.5M |
| IPO Year | 2016 | 2020 |
| Metric | MRAM | AVIR |
|---|---|---|
| Price | $9.09 | $3.97 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 3 |
| Target Price | ★ $25.50 | $9.00 |
| AVG Volume (30 Days) | ★ 617.9K | 264.6K |
| Earning Date | 10-28-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.00 |
| EPS | ★ N/A | N/A |
| Revenue | $49,417,000.00 | ★ $351,367,000.00 |
| Revenue This Year | $37.27 | N/A |
| Revenue Next Year | $16.63 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 37.51 | N/A |
| 52 Week Low | $7.48 | $2.96 |
| 52 Week High | $51.50 | $6.45 |
| Indicator | MRAM | AVIR |
|---|---|---|
| Relative Strength Index (RSI) | 29.32 | 38.55 |
| Support Level | $8.43 | N/A |
| Resistance Level | $9.88 | $4.54 |
| Average True Range (ATR) | 0.99 | 0.24 |
| MACD | -0.21 | 0.00 |
| Stochastic Oscillator | 0.70 | 28.06 |
Everspin Technologies Inc is a manufacturer of Magnetoresistive Random Access Memory (MRAM) technology. The company manufactures MRAM products using both captive and third-party manufacturing capabilities. It purchases industry-standard complementary metal-oxide semiconductor (CMOS) wafers from semiconductor foundries and perform back end of line (BEOL) processing that includes magnetic-bit technology at leased 200mm fabrication facility in Chandler, Arizona. It also manufactures full-flow 300mm CMOS wafers with STT-MRAM magnetic-bit technology integrated in BEOL. The company's customers are in key markets, such as industrial, medical, automotive/transportation, aerospace, and data center.
Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.